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ABSTRACT
Early after estrogen loss in postmenopausal women and ovariectomy (OVX) of animals, accelerated endosteal bone resorption leads to
marrowexpansionoflongboneshaftsthatreducemechanicalintegrity.Bothgrowthhormone(GH)andinsulin-likegrowthfactor(IGF-1)
are potent regulators of bone remodeling processes. To investigate the role of the GH/IGF-1 axis with estrogen deficiency, we used the
liver IGF-1-deficient (LID) mouse. Contrary to deficits in controls, OVX of LID mice resulted in maintenance of cortical bone mechanical
integrity primarily owing to an enhanced periosteal expansion affect on cross-sectional structure (total area and cortical width). The
serum balance in LID that favors GH over IGF-1 diminished the effects of ablated ovarian function on numbers of osteoclast precursors in
the marrow and viability of osteocytes within the cortical matrix and led to less endosteal resorption in addition to greater periosteal
bone formation. Interactions between estrogen and the GH/IGF-1 system as related to bone remodeling provide a pathway to minimize
degeneration of bone tissue structure and osteoporotic fracture.  2010 American Society for Bone and Mineral Research.
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Introduction
I
nsulin-like growth factor (IGF-1) is a major regulator of skeletal
growth and remodeling.
(1–3) In vivo, IGF-1 mediates the effects
of growth hormone (GH) on longitudinal bone growth, whereas
in vitro, it is a mitogen for preosteoblasts and promotes their
ability to mineralize in culture.
(4–6) Studies by us and others have
shownthatIGF-1actsonboneviabothendocrineandautocrine/
paracrine pathways.
(1–3,7) Endocrine regulation of bone is
mediated by circulating IGF-1, which is the most prevalent
peptide hormone secreted by the liver
(4); autocrine/paracrine
regulation depends on skeletal IGF-1 produced by osteoblasts
and by stromal cells of bone marrow.
(5)
One of the factors regulating the expression of IGF-1 is
estrogen, a steroid hormone whose role in maintaining skeletal
integrity through effects on bone remodeling has been
documented extensively.
(8–10) Loss of estrogen in postmeno-
pausal women, ovariectomized animals, or men deficient in the
production and/or response to estrogen in peripheral tissues
results in increased bone turnover and a net increase in bone
resorption over formation, resulting in reduced bone mineral
density (BMD).
(11–13) In addition to inhibiting production of
proresorptive cytokines such as tumor necrosis factor a (TNFa),
interleukin 1 (IL-1), IL-6, IL-7, and receptor activator of NF-kB
(RANKL) by osteoclast-supportive bone marrow (BM) stromal
cells, monocytes, and lymphocytes,
(14,15) estrogen has been
shown to stimulate IGF-1 expression by osteoblastic cells.
(16)
Moreover, the liver responds to sex steroids, and numerous
clinical and animal studies have shown that sex steroids can
modulate GH secretion (at the level of the pituitary) as well as its
action in target tissues (i.e., liver or bone).
(17) Finally, serum GH
levels correlate positively with estrogen, and estrogen-replace-
ment therapy in postmenopausal women increases serum GH,
even though serum IGF-1 levels are decreased.
(18,19) These
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235findings indicate that complex interactions between the GH/IGF-1
and estrogen axes may contribute to skeletal maintenance, and
suggest that treatment with GH may have potential benefit in
postmenopausal bone loss.
Because estrogen can regulate circulating IGF levels via
actions in both the liver and pituitary (through GH), we
hypothesized that the skeletal response to ovariectomy-induced
bonelosswouldbealterediftheabilityofthelivertoexpressand
producecirculatingIGF-1werelimited.Wetestedthishypothesis
using the LID mouse system generated using the Cre-loxP
system.
(20) LID mice Exhibit 75% lower circulating IGF-1 levels
and three- to fourfold greater serum GH levels than controls.
Materials and Methods
Animals
We previously described the generation and genotyping of LID
mice.
(20) Briefly, LID mice were generated using the Cre-loxP
system, whereby exon 4 of the IGF1 gene is flanked by two loxP
sites, and the Cre recombinase Tg is expressed specifically in the
liver under the albumin enhancer-promoter sequence. PCR was
used for genotype determination of littermates with specific
primers and tail DNA extracts. The following primers were
employed: 5‘-AAA CCA CAC TgC TCg ACA TTg, 5‘-AgT gAT Agg
TCA CAA AgT TCC, and 5‘-CAC TAA ggA gTC TgT ATT Tgg ACC to
detect the WT and IGF1 recombinant allele. The Cre recombinase
Tg was detected with 5‘-AAT gCT TCT gTC CgT TTg CCg gT and
5‘-CCA ggC TAA gTg CCT TCT CTA CA.
Separate, nonoperated basal control groups of 12-week-old
mice (n¼8 per group) were sacrificed at the beginning of the
experiment to account for growth. Mice were caged in groups of
four or five and fed ad libitum. Body weight (BW) and
composition (see below) were measured every 4 weeks. The
IACUCattheMountSinaiSchoolofMedicineapprovedallanimal
study protocols. All protocols requiring anesthesia used 3%
inhaled isofluorane (Baxter) in 1L/min oxygen. No mice died
unintentionally over the experimental periods.
Ovariectomy
Mice were anesthetized, the lumbar dorsum shaved bilaterally,
and the exposed skin prepared for aseptic surgery. For each
ovary, a single 0.7cm dorsal flank incision penetrating the
abdominal cavity was made. The exposed ovary was removed by
scalpel excision, and homeostasis was achieved by hemostat
pressure for 1 to 2 minutes. The incisions were closed with
nonabsorbable suture. Injection (s.c.) of buprenorphine hydro-
chloride (0.05mg/kg, Reckitt Benckiser PLC) provided post-
operative analgesia.
Body composition
Fat mass was assessed in live (nonanesthetized) animals using
EchoMRI (3-in-1, Echo Medical Systems). This technique allows
serial measurements of fat and lean mass with high levels of
precision and without affecting the subjects tested. The
measurement of each mouse lasted 90 seconds, and the
precision of the measurement is 0.1 to 0.3 SD.
Blood and tissue collection
Mice were anesthetized and mandibular bleeding performed to
obtain serum samples. Liver, bone marrow (BM) and bones were
dissected immediately after euthanasia and frozen in liquid
nitrogen or fixed in 10% neutral phosphate-buffered formalin
(PBF). Bones for micro-computed tomography (mCT) and
mechanical testing were stored at  208C.
Serum hormones
IGF-1
Serum concentrations were measured using an RIA with a
polyclonal human anti-IGF-1 Ab that has been validated
previously in mice.
(7) The sensitivity of measurement is 0.3ng/
mL; there is no cross-reactivity with IGF-2, the interassay CV is 4.6%,
and the intraassay CV is 2.3%. Known standards were placed in
each run, and pooled mouse serum from C57BL/6J mice at
16 weeks of age was used as another control for assay variation.
GH
Serum concentrations were determined using an RIA kit with a
sensitivity of 0.02ng/mL (National Hormone and Pituitary
Program, Harbor-UCLA Medical Center, Los Angeles, CA).
IGFBP
Serum levels of mouse IGF-binding protein-3 (IGFBP-3) were deter-
mined with ELISA assays developed at UCLA using recombinant
mouse proteins from R&D and mAb as described previously.
(21)
mCT
Three-dimensional mCT (mCT40, Scanco Medical AG) was used to
assessbonestructure usinga12mmisotropicvoxelresolution, as
described elsewhere.
(22) All morphometric traits were computed
from binarized images using direct 3D techniques that do not
rely on any prior assumptions about the underlying structure.
(23)
Nomenclature adheres to that recommended by the Histomor-
phometry Nomenclature Committee of the American Society for
Bone and Mineral Research.
(24) For distal femoral metaphyses,
trabecular bone volume (BV/TV), trabecular thickness (Tb.Th),
trabecular number (Tb.N), trabecular span (Tb.Sp), and con-
nectivity density (Conn-Dens) were quantified. Middiaphyseal
morphologic traits measured were Tt.Ar, Ct.Ar, Ma.Ar, Ct.Wi, and
cross-sectional moment of inertia (CSMI). The diaphyseal
site corresponded to the typical location of failure during the
bendingtests (see below).For qualityassurance, wefollowed the
manufacturer’s recommendations, which include weekly scans
of a set of hydroxyapatite phantoms, weekly archiving of data
and system software, and an annual maintenance and service
visit by a Scanco Medical technician.
Whole-bone mechanical testing
Long bone length was measured as the caliper distance
(0.01mm resolution) between the most proximal and distal
articulating surfaces of the femoral head and condyles,
respectively.Themechanicalpropertiesofmiddiaphysealfemurs
then were quantified by loading to failure in four-point bending
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(Instron Corporation).
(25,26) The four-point bending test allows
comparison of mechanical properties as calculated from the load
and displacement signals. Femurs were tested at room
temperature and kept moist with PBS. Each femur was placed
with the caudal surface down on two lower supports. The lower
and two upper supports were set apart at 6.35 and 2.2mm,
respectively, and loading was centered over the middiaphysis.
Load and displacement signals were bridge amplified, with the
same gain in each test. These signals, comprising the load-
deflection curves, were fed to a Gateway PC equipped with a
National Instruments AT-MIO 16-bit analog-to-digital (A/D)
board. The A/D board was configured as single-ended with a
range of  10V. Digital sampling was accomplished at 100Hz
with custom-coded lab software using the LabView package
(Version 6, National Instruments). Maximum signal intensity
withoutlossofdataowingtodigitizationwasensuredbyuseofa
protocol for similar-sized mouse femurs, and data cutoff was not
observed. Load-deflection curves were analyzed with custom-
coded LabView software (courtesy of Dr. Karl J Jepsen) for
stiffness (the slope of the initial linear portion of the curve) and
strength (maximum load).
Bone histomorphometry
Because differences in skeletal organization and mechanical
properties may arise from differences in bone formation,
resorption, or both, we carried out histomorphometric assess-
ments of these processes in the tibial middiaphysis as describ-
ed in detail elsewhere.
(24,25) Briefly, calcein (10mg/kg, Sigma
C-0875) labels were injected intraperitoneally at 8 and 2 days
prior to euthanasia to label bone-forming surfaces (osteoblast
activity). Followingeuthanasia, tibiaswereremoved,fixedin10%
neutral PBF, bulk stained with Villanueva bone stain, and
embedded in poly-methyl methacrylate. Embedded bones were
sectioned transversely at the middiaphysis with a diamond-
coated wafering saw (Leica), polished to a thickness of 30mm
with silicon carbide abrasive paper, and mounted on slides.
Cortical bone indices of static bone geometry (Tt.Ar, Ct.Ar, and
Ma.Ar) and osteoblast bone formation (L.Pm/B.Pm and MAR) and
osteoclast bone resorption (Er.Pm/B.Pm) activity on both
periosteal and endosteal surfaces were analyzed using an
OsteoMeasure system (Osteometrics, Decatur, GA) on a Zeiss
Axioskop microscope with fluorescence and brightfield cap-
ability.
(24) Area fractions (Ct.Ar/Tt.Ar and Ma.Ar/Tt.Ar) and bone-
formation rate (BFR/B.Pm, the product of MAR and L.Pm/B.Pm)
were calculated.
(24) A single observer blinded to the specimen
identity made all measurements.
Osteocyte apoptosis
The spatial patterns of osteocyte apoptosis were assessed in
middiaphyseal femoral cortices using immunohistochemistry
for apoptotic markers.
(27) To detect osteocyte apoptosis, 5mm
thick paraffin sections were cut and incubated with primary
Ab to cleaved (activated) caspase-3 (Cell Signaling No. 9661, at
1:50 dilution in Ab diluent, DakoCytomation, Carpinteria, CA).
Sections were adhered to positively charged slides, deparaffi-
nized, rehydrated, and then treated with 3% hydrogen peroxide
to block endogenous peroxidase activity. Antigen retrieval was
performed using a methanol-NaOH-based solution for 30 min-
utes at room temperature (DeCal Retrieval Solution, Biogenex,
San Francisco, CA). Before addition of primary Ab, nonspecific
tissue binding was blocked by incubating tissue sections in 10%
rabbit serum in PBS for 30 minutes at room temperature.
Sections were incubated with rabbit antimouse cleaved caspase-
3 primary Ab to identify cells undergoing apoptosis. Sections
were incubated in primary Ab overnight at 4 8C in a humidified
chamber. Detection was performed using a goat antirabbit
secondary Ab labeled with a horseradish peroxidase conjugate
and developed with a 3,3’-diaminobenzidine (DAB) substrate
chromogen system (DakoCytomation); fast-green was used as a
counterstain. Apoptotic osteocytes (caspase-positive) were
counted under brightfield microscopy at  400 magnification
using a 10 10mm eyepiece grid reticule. Osteocytes were
counted through the entire cortical width for each of eight
sampling regions around the cross section.
Liver expression of GH receptor and BP
In the circulation, GH is bound to a high-affinity binding protein
(GHBP) that affects its pharmacokinetics and bioactivity.
However, the biologic role of GHBP is not yet clear. In cell
culture systems, GHBP antagonizes GH actions, and in animal
models, administration of GHBP was shown to enhance GH
bioactivity and prolong GH half-life in serum.
(28) We examined
expression of GHBP and GH receptor (GHR) levels in livers of all
groups at baseline and 4 weeks postoperatively. One microgram
of total RNA was extracted from livers and reverse-transcribed to
cDNA.Real-timePCRsofGHR,GHBP,andb-actinwereperformed
using specific primers.
BM fluorescence-activated cell sorting
We assessed changes in the immune cell populations of BM
isolates from control and LID mice at 4, 8, and 16 weeks
postoperatively. We focused on two cell populations identified
by specific cell surface markers: (1) B220, a marker of pre-pro-B
cells, which produce membrane-bound and secreted RANKL, an
essential differentiation factor for osteoclasts, and (2) CD11b,
a marker of the myeloid lineage from which osteoclasts
differentiate on stimulation with RANKL/M-CSF. BM cells were
harvested from the femur, washed with PBS, and resuspended in
staining buffer (PBS, 0.5% FBS, 0.09% sodium azide): 10
6 cells
were preincubated with rat antimouse CD16/CD32 (1mg, BD
Biosciences, San Diego, CA) for 10 minutes at 48C to block Fc
receptors. Cells were incubated for 30 minutes at 48C with
fluorescently labeled Ab: R-Phycoerythrin (PE)-c-Fms/CSF-1R
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), PE-Cy7-
conjugated rat antimouse CD45R/B220, and Alexa Fluor 647-
conjugated rat antimouse CD11b (BD Biosciences). The cells
were washed with cold PBS buffer. BM cells then were
resuspended in PBS containing 1% paraformaldehyde. Cell
acquisition was performed in a flow cytometer (FACScan, Becton
Dickinson, Franklin Lakes, NJ), and at least 10,000 events were
acquired for each test. Data were analyzed with FlowJo software
(Version 7.2). R-PE-conjugated mouse IgG2b and Alexa Fluor
647-conjugated mouse IgG2a isotype controls were used. Cells
were stained with Streptavidin-FITC diluted 1:100 as control.
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Differences in trait values among the groups and all time points
were assessed individually by two-way ANOVA with interaction.
The type I error rate (a) was set at 0.05. Differences between
groups at individual time points were compared using post hoc
Bonferroni-adjusted multiple comparisons (SYSTAT Software,
SPSS Science, Chicago, IL).
Results
Changes in body adiposity in control and LID mice
Intact LID female mice had a lower BW than control mice at
12 weeks of age and remained smaller at all ages examined
(Fig. 1A). OVX did not alter body mass in control mice but
resulted in substantial weight gains in the LID mice so that their
Fig. 1. The effects of OVX on body composition and serum levels of IGF-1, IGFBP-3, and GH in 12-week-old (basal) control and LID female mice. (A)B W
measured from 12 to 28 weeks of age.(B) Bodyadiposity assessedby MRI. (C) Serum IGF-1 determinedby RIA. (D) Serum levels of GH in sham-operated (S)
miceandmiceafterOVX(O)determinedbyELISA.(E)SerumIGFBP-3levelsdeterminedbyELISA.( F)Uterusweightat4weeksaftersurgery,n¼8miceper
group, except sham-operated control mice. where n¼4. For longitudinal measurements (A–D), n¼8 to 47 mice per group. Data are represented as
mean SEM at p<.05. a¼LID versus sham-operated control or basal mice of same age group (significant genotype effects); b¼versus sham-operated
mice of same genotype and age group (significant OVX effects).
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age-matched controls. MRI verified that the increased BW in LID
mice following OVX was due to increased body fat mass (see
Fig. 1B).
Serum levels of IGF-1, IGFBP-3, and GH
LID mice exhibit 75% lower serum IGF-1 levels than control mice
at birth, and this difference persists throughout life with no
evident changes in IGF1 gene expression in other tissues.
(20) OVX
did not affect serum IGF-1 levels in LID or control mice (see
Fig. 1C). In contrast, serum GH levels responded differently to
OVX in control and LID mice. At 16 weeks of age (4 weeks
postoperatively), sham-operated LID mice had roughly sixfold
greater serum GH levels than controls, but this difference was no
longerevident at24 weeks, indicatingan age-relateddecrease in
serum GH levels (see Fig. 1D). In OVX mice, however, GH levels
were about 1.6-fold greater in LID mice than in controls at
16 weeks (4 weeks after OVX), and at 24 weeks of age (12 weeks
after OVX), GH levels remained elevated, resulting in a roughly
threefold increase relative to control mice. Alongside a lower
serumIGF-1level,IGFBP-3,themaincarrierofIGF-1incirculation,
alsowaslowerinLIDmicethanincontrols,asexpectedgiventhe
direct dependency of IGFBP-3 on IGF-1.
(18) This difference
persisted at 4 weeks postoperatively (see Fig. 1E). As expected,
OVX reduced uterine mass in both control and LID mice and to a
similar extent ( 75%) versus sham-operated animals (see
Fig. 1F).
Structural and mechanical properties
The structural consequences of serum IGF-1 and estrogen
deficiencies on long bones were revealed by mCT (Fig. 2A and
Table 1). Femurs of LID mice were thinner than controls at all
ages based on Tt.Ar at the middiaphysis (see Fig. 2A).
Additionally, LID mice exhibited a smaller cortex thickness
(Ct.Wi). The effects of OVX also differed between control and LID
mice. OVX led to a decrease in Tt.Ar and the expected cortical
thinning (smaller Ct.Wi) in controls, whereas expansion of the
periosteal envelope in LID mice shortly after OVX resulted in
larger Tt.Ar and maintenance of Ct.Wi.
Mechanical testing and structural data were consistent. The
thinner femoral diaphyses of LID mice had lower strength
(maximum load) than controls at all ages (see Fig. 2B). Likewise, a
thinner middiaphysis observed after OVX of control mice was
associated with lower strength and stiffness at 24 weeks of age
(see Fig. 2B, C). Conversely, OVX of LID mice did not result in
reduced mechanical properties.
Bone resorption and formation
Differences between control and LID mice in structural features
and responses to OVX measured by histomorphometry were
comparable with those observed by mCT (Fig. 3 and Table 2). In
control mice, the eroded (resorbing) fraction (Er.Pm/B.Pm) of the
endosteal surface increased with time after OVX. In LID mice,
endosteal resorption also increased, although to a lesser degree
thanseenincontrolmice.InbothcontrolandLIDsham-operated
mice, there was no change in endosteal bone formation (L.Pm/
B.Pm) over time. However, in control mice, OVX caused a
Fig. 2. Femoral midshaft structural and biomechanical properties deter-
mined by mCT and four-point bend test, respectively. (A) Total area at the
femoral midshaft. Maximum load (B) and stiffness (C) sustained by the
femoralmidshaft.Dataarerepresentedas mean SEM.Groupsizeswere
basal: control (n¼7), LID (n¼8); 16 weeks: sham-operated control
(n¼4), OVX control (n¼7), sham-operated LID (n¼8), OVX LID
(n¼8); 24 weeks: sham-operated control (n¼7), OVX control (n¼7),
sham-operated LID (n¼7), OVX LID (n¼8); and 28 weeks: sham-oper-
ated control (n¼10), OVX control (n¼15), sham-operated LID (n¼9),
OVX LID (n¼19). p<.05. a¼LID versus sham-operated control or basal
mice of same age group (significant genotype effects); b¼versus sham-
operated mice of the same genotype and age group (significant OVX
effects).
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LID mice at 8 weeks after surgery (see Fig. 3A). While differences
in resorption were not observed on the periosteal surface, L.Pm/
B.Pm and, consequently, BFR were significantly greater after OVX
in LID mice only (see Fig. 3B and Table 2).
Ovariectomy-induced osteocyte apoptosis
We detected a twofold increase in osteocyte apoptosis based on
immunohistochemical staining for activated caspase-3 in control
mice 4 and 8 weeks after OVX (Fig. 4). In LID mice, we observed a
Table 1. Indices From mCT of Femurs From Control and LID Mice at Baseline (12 Weeks of Age) and at 4, 12, and 16 Weeks After Surgery
Age Location Variable Control LID
12 weeks, basal Distal femur BV/TV (%) 15 0.69 12 0.66
a
Conn-Dens (1/mm
3) 134 9.1 121 10.2
Tb.N (1/mm) 4.4 0.09 4.2 0.11
Tb.Th (mm) 51 0.49 47 0.52
a
Tb.Sp (mm) 225 5.5 240 6.6
Mid-diaphysis femur Ct.Ar (mm
2) 0.61 0.02 0.48 0.01
a
Ma.Ar (mm
2) 0.83 0.01 0.71 0.02
a
Ct.Ar/Tt.Ar (%) 42 0.74 40 0.48
Ct.Wi (mm) 163 3.90 140 1.86
a
CSMI (mm
4) 0.22 0.008 0.14 0.006
a
Location Variable Sham control OVX control Sham LID OVX LID
16 weeks Distal femur BV/TV (%) 11 1.25
c 9.9 0.48 9.7 0.50 8.4 0.23
Conn-Dens (1/mm
3) 81.0 14.3
c 65.0 7.0 83.7 7.9
c 69.7 3.6
Tb.N (1/mm) 3.7 0.19
c 3.5 0.09 3.5 0.10
c 3.2 0.08
Tb.Th (mm) 53 1.07 48 1.21
b 47 0.29
a 47 0.73
Tb.Sp (mm) 273 14.1 314 16.7 293 8.3 324 8.3
Mid-diaphysis femur Ct.Ar (mm
2) 0.67 0.01 0.61 0.03
b 0.48 0.01
a 0.53 0.02
Ma.Ar (mm
2) 0.79 0.01 0.77 0.03 0.66 0.01
a 0.72 0.02
Ct.Ar/Tt.Ar (%) 46 0.53
c 44 0.81 42 0.55
a 42 0.63
Ct.Wi (mm) 179 3.17
c 169 5.10
b 145 2.07
a 153 3.66
CSMI (mm
4) 0.23 0.006 0.17 0.028
b 0.13 0.004
a 0.16 0.010
24 weeks Distal femur BV/TV (%) 6.5 0.43
c,d 8.7 1.34 7.7 0.87 4.8 0.43
a,b,d
Conn-Dens (1/mm
3) 19.2 3.2
c,d 53.3 14.5
b,d 51.6 9.1
a,c,d 25.3 4.1
a,d
Tb.N (1/mm) 2.8 0.09
c,d 2.9 2.8 3.0 0.18
c 2.4 0.07
b,d
Tb.Th (mm) 53 1.20 50 1.02 45 0.53
a 45 0.57
a
Tb.Sp (mm) 367 12.7 364 29.6 342 22.8
c 424 12.3
b,d
Mid-diaphysis femur Ct.Ar (mm
2) 0.67 0.01 0.59 0.02
b 0.51 0.01
a 0.52 0.02
a
Ma.Ar (mm
2) 0.71 0.01
c 0.71 0.02 0,5 0.01
a,c,d 0.67 0.01
b
Ct.Ar/Tt.Ar (%) 48 0.42
c 46 0.34
b 48 0.57
c,d 44 0.60
b
Ct.Wi (mm) 188 2.24
c 169 3.40
b 164 3.32
a,c,d 155 4.25
a
CSMI (mm
4) 0.21 0.005 0.19 0.014 0.13 0.004
a 0.15 0.010
28 weeks Distal femur BV/TV (%) 5.9 0.46
c,d 5.8 0.53
d,e 6.4 0.54
d 5.3 0.28
d
Conn-Dens (1/mm
3) 19.0 2.9
c,d 22.9 3.5
d,e 40.5 5.7
c,d,e 27.7 2.4
d
Tb.N (1/mm) 2.6 0.06
c,d 2.3 0.06
d,e 2.7 0.13
c,d 2.1 0.09
b,d
Tb.Th (mm) 52 1.28 50 0.59 46 0.88
a 46 0.43
a
Tb.Sp (mm) 387 12.1
c,d 437 11.1
d,e 386 26.5
c,d 491 21.5
b,d,e
Mid-diaphysis femur Ct.Ar (mm
2) 0.65 0.02 0.61 0.01 0.49 0.01
a 0.49 0.00
a
Ma.Ar (mm
2) 0.70 0.02
c,d 0.71 0.01 0,5 0.01
a,c,d 0.64 0.01
a,b,d
Ct.Ar/Tt.Ar (%) 48 0.50
c 46 0.44
b,d 47 0.41
c,d 44 0.34
a,b
Ct.Wi (mm) 185þ3.70
c 173 2.41
b 159 2.12
a,c,d 151 1.17
a
CSMI (mm
4) 0.21þ0.012 0.19 0.007 0.12 0.004
a 0.14 0.008
a
Data are presented as mean SEM. Sample sizes were basal: control (n¼8), LID (n¼8); 16 weeks: sham control (n¼4), OVX control (n¼8), sham LID
(n¼8), OVX LID (n¼8); 24 weeks: sham control (n¼7), OVX control (n¼7), sham LID (n¼7), OVX LID (n¼8); and 28 weeks: sham control (n¼10), OVX
control (n¼15), sham LID (n¼9), OVX LID (n¼19) at p<.05. Ct.Wi¼cortical width; CSMI¼cross-sectional moment of inertia; Conn-Dens¼connectivity
density.
aVersus control mice of the same surgical and age group (significant genotype effects),
bVersus sham-operated mice of the same genotype and age group (significant OVX effects),
c,d,eVersus. 12, 16, or 24 weeks, respectively, of same surgical and genotype group (significant age effects).
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at 8 weeks after OVX, the number of apoptotic osteocytes was
comparable with that in sham-operated control mice.
OVX increased GH sensitivity in LID mice
Femoral length, which depends strongly on GH activity, was not
affected by OVX in control mice at 4, 12, and 16 weeks following
surgery (Fig. 5A). However, LID mice experienced a significant
increase ( 4%) in femoral length. This suggests that in the face
ofreducedserumIGF-1levels,LIDmiceexperienceanincreasein
GH activity in bones following OVX.
Real-time PCR revealed a decrease in GHBP/GHR expression in
response to OVX in both control and LID mice (see Fig. 5B).
LID mice show reduced numbers of lymphoid (B220) and
myeloid (CD11b) cells in bone marrow
LID mice exhibited significant reductions in B220þ and CD11bþ
cells at all time points after surgery (Fig. 6). These data are in
accordance with our previous finding of reduced resorption in
LID mice after OVX.
Discussion
The results of this study clearly demonstrate that the skeletal
response to estrogen deprivation can be modulated to a large
extent by alterations in the GH/IGF-1 regulatory axis, specifically
by changes in the circulating levels of IGF-1 and GH. Control and
LID mice exhibited marked differences in both bone resorption
and formation that were associated with changes in osteocyte
apoptosis as well as the content of immune-related cells in BM
(Fig. 7). In addition, we observed a surprising increase in
longitudinal femur growth of LID mice following OVX, an effect
that may be directly attributable to increased circulating GH
levels in the face of reduced circulating IGF-1 in LID mice.
Not surprisingly, as reported previously by our group, LID mice
show increased GH throughout adolescence and into adulthood
owingtoimpairedfeedbackinhibition bycirculating IGF-1.
(20)An
additional and well-recognized modulator of GH is estrogen.
However, estrogen effects on GH have been inconsistent, with
studies showing either stimulation or inhibition. Oral estrogens
inhibit the actions of GH in the liver. Clinically, this effect is
observed in a number of different conditions, including estrogen
supplementationingirlswithdelayedpubertyandconstitutional
tall stature and postmenopausal or hypopituitary women.
(29–31)
In GH-deficient patients, serum IGF-1 levels are lower in females
than in males, and when given GH-replacement therapy, females
require a higher dose of GH to get an increase in serum IGF-1
levels similar to males.
(32) Thus there appears to be GH resistance
to exogenous and endogenous estrogen. We found increased
bone apposition, length, and width to occur principally within
the first 4 weeks of OVX in LID mice. However, during this period,
GH levels dropped. Estrogen is known to modify peripheral
responses to GH.
(33) Therefore, we postulate that in the absence
of estrogen, LID mice have increased sensitivity to GH. Centrally,
we found that OVX resulted in a decreased GHR/GHBP
expression in the liver. Together these data suggest that in
the absence of estrogen there is an increased response to and
increased bioavailability of GH in serum of LID mice.
Our data demonstrate that dysregulation of the GH/IGF-1–
estradiol axis has consequences for the mechanical integrity of
the diaphysis.In12-week-old LIDmice,biomechanicalproperties
and cross-sectional morphology were different than in age-
matched controls. Biomechanical properties, including max-
imum load, are indicators of resistance to fracture and normally
are directly related to BW and/or lean mass. However, this
relationship is confounded with the loss of estrogen, such as at
female menopause, when BW and adiposity increase, whereas
lean mass, bone mass, and biomechanical properties decrease,
resulting in an increased risk of fracture.
(34) OVX of LID mice was
associatedwithgreaterBWandadiopositycomparedwithsham-
operated LID mice. After OVX, LID mice did not exhibit reduced
diaphyseal cortical biomechanical properties, in agreement with
greater midshaft structural properties (Tt.Ar and Ct.Wi). This was
insharp contrasttothenormalchangesobservedafterdepletion
of estrogen in control mice (see Fig. 7). Femoral Tt.Ar remained
Fig. 3. Histomorphometry at the tibial midshaft of control and LID mice
at 4 and 8 weeks postoperatively. Endosteal (A) and periosteal (B) eroded
surfaceandlabeledsurfaceexpressedas perimeterfractions(Er.Pm/B.Pm
and L.Pm/B.Pm). Sample sizes were n¼4 per group, except for 20-week-
old (8 weeks after surgery) sham-operated groups, which were n¼3 per
group. Data are represented as mean SEM at p<.05. a¼versus control
mice of same surgical and age group (significant genotype effects);
b¼versus sham-operated mice of the same genotype and age group
(significant OVX effects).
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to 16 weeks (p¼.06) after surgical intervention, the last time
point examined.
Data on the biomechanical consequences of an impaired GH/
IGF-1 axis had not been reported previously. However, studies in
adult dogs and rats show that GH treatment can increase bone
mass in a dose-dependent manner.
(35,36) Additionally, exogen-
ous administration of recombinant human GH into aged rats
with OVX prevents further trabecular bone loss and increases
cortical bone mass above pretreatment values.
(37–39) However,
these previous exogenous GH studies did not attempt to
separate out effects of other hormones or explore the cellular
mechanisms driving increased bone apposition; the exogenous
administrationofeitherIGF-1orGHincreasescirculatinglevelsof
GH or IGF-1, respectively. In our LID mouse model with high
baseline GH, increased cortical bone apposition and mechanical
integrity occurred only after OVX and without a significant
alterationinthe low levelof circulatingIGF-1. Combined withthe
previous body of work, these results argue for a direct peripheral
effect of GH on bone formation. Importantly, these newdata also
suggest that starting GH hormone treatment prior to loss of
estrogen should be further explored for protective effects on the
skeleton.
Table 2. Indices From Histomorphometry of Cortical Bone at the Tibial Midshaft 4 and 8 Weeks After Ovariectomy (16 and 20 Weeks of
Age)
Age Variable Sham control OVX control Sham LID OVX LID
16 weeks Tt.Ar (mm
2) 0.79 0.04 0.86 0.02 0.65 0.02
a 0.71 0.04
a
Ma.Ar/Tt.Ar (%) 21 1.8 29 2.9
b 19 0.02 20 1.4
a
Endosteal surface: Tt.Ar (mm
2)
Er.Pm/B.Pm (%) 2.4 1.9 12 3.7
b 4.3 3.0 12 2.7
b
L.Pm/B.Pm (%) 49 7.4 40 3.0 64 2.3
a 60 4.0
a
MAR (mm/d) 1.08 0.11 0.94 .09
b 1.11 0.06
a 1.08 0.12
BFR/B.Pm (mm/d
 100) 52.9 9.7 36.9 4.5
b 70.4 4.4
a 63.9 5.6
a
Periosteal surface:
Er.Pm/B.Pm (%) 9.8 4.4 8.9 1.5 7.9 2.6 6.0 2.1
L.Pm/B.Pm (%) 21 4.7 17 4.2 18 2.0 18 1.6
MAR (mm/d) 0.06 0.07 0.42 0.19
b 0.20 0.15 0.42 0.21
BFR/B.Pm (mm/d
 100) 2.00 2.31 8.52 4.55
b 3.75 2.53 7.29 4.29
20 weeks Tt.Ar (mm
2) 0.89 0.01 0.76 0.01
b 0.74 0.08
a 0.67 0.01
Ma.Ar/Tt.Ar (%) 27 2.4 31 2.5 29 3.4 24 0.4
a
Endosteal surface: Tt.Ar (mm
2)
Er.Pm/B.Pm (%) 6.0 4.4 30 2.6
b 0.88 1.1 17 7.4
a,b
L.Pm/B.Pm (%) 47 3.8 27 6.3
b 59 6.6
a 48 4.9
a
MAR (mm/d) 0.88 0.10 0.37 0.17
b 0.97 0.08 0.62 0.17
b
BFR/B.Pm (mm/d
 100) 41.8 7.2 11.0 6.0
b 57.4 4.0
a 28.4 6.7
a,b
Periosteal surface:
Er.Pm/B.Pm (%) 8.1 1.2 5.0 3.4 4.1 1.5
a 3.5 2.4
L.Pm/B.Pm (%) 9.9 4.2 16 3.7 7.6 3.5 22 9.7
b
MAR (mm/d) ND 0.31 0.20 0.15 0.18 0.35 0.27
BFR/B.Pm (mm/d
 100) ND 4.5 3.0 1.5 1.8 11.6 8.3
b
Double labels were not detected (ND) on the periosteal surface of 20-week sham control mouse tibias. Data are presented as mean SEM. Sample sizes
were 16 weeks: n¼4 per group; and 20 weeks: sham control (n¼3), OVX control (n¼4), sham LID (n¼3), OVX LID (n¼4) at p<.05.
aVersus control mice of the same surgical and age group (significant genotype effects).
bVersus sham-operated mice of the same genotype and age group (significant OVX effects).
Fig. 4. Apoptotic osteocyte density was increased after OVX and was
lower in LID mice. Osteocyte apoptosis was assessed by immunohisto-
chemistry using caspase-3 Ab on 5mm paraffin sections of the femoral
midshaft. Sample sizes were n¼4 per group, except for the 20-week-old
(8weeksaftersurgery)sham-operatedgroups,thatweren¼3pergroup.
Data are represented as mean SEM at p<.05. a¼sham-operated LID
mice versus sham-operated control mice of same age group (significant
genotypeeffects);b¼versussham-operatedmiceofsamegenotypeand
age group (significant OVX effects).
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of the GH/IGF-1 axis. Studies in adult and adolescent female
rhesus monkeys with OVX show that estradiol stimulates GH and
IGFBP-3. Yet an increase in serum IGF-1 is restricted to
adolescence, so in postpubertal young-adult females estradiol
reduces serum IGF-1.
(40) In this current study we chose an age for
OVX at which mice were not growing rapidly (12 weeks).
Additionally, we included basal groups as controls for age-
related differences. The pubertal growth spurt was nearly
complete, as evidenced by the low rate of longitudinal growth
over our 16-week experimental period (femur  2%). However,
BW was increased, whereas serum GH was decreased drama-
tically without any intervention. In adult mice, these differences
are indicative of overall aging. However, we cannot rule out that
OVX of older LID mice might not lead to the same suppression of
endosteal osteoclast activity and enhancement of osteoblast
activity as observed in this study because the physiologic milieu
(stem cells, growth factors, etc.) changes with age and could
affect boneresorptionandformation. InastudywithGHTg mice,
which express GH under the metallothionein promoter,
increased tibial and vertebral bone volumes were revealed.
(41)
OVX of these mice resulted in bone loss, suggesting that the GH
effects in bone depend on the presence of sex steroids, although
OVX was performed at 4 weeks of age, a period of rapid growth.
Our histomorphometry data indicate that reduced serum IGF-
1 was associated with reduced resorption and greater formation
surface. We speculate that these resorptive and formative effects
were due mainly to less circulating IGF-1 and more circulating
GH, respectively. Our speculations are based on the effects of
serum IGF-1 in promoting myeloid precursor populations
(42,43)
and GH in increasing bone growth and mass via effects on
osteoblasts.
(4,38,39,41) However, owing to their complex and
integral relationship, as discussed previously, the separation of
GH and IGF-1 effects in vivo continues to be actively pursued in
manylaboratories,includingourown,whereweareapproaching
the problem by the generation of novel inducible gene-
expression mouse models. In both LID and control mice, the
largest effect of OVX on resorption activity was measured on the
endosteal surface (see Fig. 3). However, the observed loss of
stiffness and strength owing to OVX in control mice is largely
accounted for by differences in periosteal-associated morphol-
ogy and consistent with smaller cross-sectional size (Tt.Ar and
Ct.Wi). Conversely, periosteal bone formation was enhanced
after OVX of LID mice (see Fig. 7), and this cellular activity
provided for unaltered or increased mechanical properties.
In addition to estrogen, adioposity is a powerful regulator of
GH.
(33) OVX was associated with a significantly greater BW and
greater adiposity in the LID mice after 4 weeks that persisted to
the last time point examined (16 weeks after OVX). BW
differences may affect bone structure and can be obviated by
pair feeding. However, the BW increase in LID mice appears to
Fig. 5. OVX increased GH sensitivity in LID mice. (A) Femur length was
measured by caliper (n¼4 to 19 per group). (B) Real-time PCR analysis of
GHBP expression in liver (n¼4 per group). Data are represented as
mean SEM at p<.05. a¼versus control mice of same surgical and age
group (significant genotype effects); b¼versus sham-operated mice of
the same genotype and age group (significant OVX effects).
Fig. 6. FACS analysis of cells derived from femoral marrow of control (C) and LID mice at the indicated ages after sham operation (S) or OVX (O) surgery at
12 weeks of age. B220þ cells (A) and CD11bþ cells (B). Data are represented as mean SEM of n>6 mice per group at p<.05. a¼versus control mice of
samesurgicalandagegroup(significantgenotypeeffects);b¼versussham-operatedmiceofthesamegenotypeandagegroup(significant OVXeffects).
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not different between control and LID mice, irrespective of
ovarian status (data not shown). Body adiposity remained
increased owing to OVX only in LID mice at 16 weeks
postoperatively, and the gap appeared to be widening along
with differences in BW. OVX of sexually mature and otherwise
normal mice does not normally lead to increased BW.
(22) We
speculate that most of the initial increase in BW in LID mice
measured at 4 weeks after OVX was due to longitudinal growth,
an effect that may be directly attributable to increased
circulating GH levels in the face of reduced circulating IGF-1.
Mainenance of this greater BW also likely was due to the greater
adiposity in LID mice. It is conceivable that part of the effects we
observed in bones of LID mice with OVX is mediated through
leptin because body adiposity correlates positively with serum
leptin levels, and leptin has been identified as a potent inhibitor
ofboneformation inmice.
(44,45) However, this isunlikelybecause
we observed greater bone formation in LID mice compared with
controls following OVX.
The cells of the immune system (B- and T-lymphocytes) also
play an important role in regulating bone turnover, and IGF-1 is a
regulator of immune function.
(42,43,46,47) Progenitors of osteo-
clasts arise from the same hematopoetic lineage as B and T
cells.
(43,47) Osteoclast differentiation acts through an axis that
includes the RANK receptor on these precursors.
(46) Therefore,
and based on previous work demonstrating that male LID mice
exhibit decreases in the myeloid cell population in BM, we
hypothesized that the chronic reduction in circulating IGF-1
would affect remodeling and reduce bone resorption through
changesintheimmuneregulatorysystem.
(48)Indeed,wefounda
decrease in B220þ cells, which express a membrane-bound and
secretedRANKL.Additionally, werevealedadecreaseinCD11bþ
cells, which are of the myeloid lineage and potentially can
differentiate to osteoclasts. Together these findings suggest that
Fig. 7. The effects of serum IGF-1 deficiency and estrogen deprivation on bone. Serum IGF-1 deficiency in LID mice results in an increase in serum GH
levels. Additionally, reductions in serum IGF-1 lead to a decrease in osteoclast (OC) progenitors through as yet undefined mechanism(s). Estrogen
deprivationinthestateofIGF-1deficiencyleadstoanincreaseinthesensitivitytoGH,asreflectedbyincreasedlineargrowthanddecreasedproductionof
GHBP by the liver. The increase in GH may protect osteocytes from OVX-induced apoptosis, leading to reduced recruitment of OC, inhibition of resorption
at the endosteal surface, and increased formation at the periosteal surface.
244 Journal of Bone and Mineral Research FRITTON ET AL.IGF-1 deficiency leads to reductions in progenitor cell popula-
tions that are important for osteoclast and osteoblast prolifera-
tion and differentiation.
Cell signaling for osteoclast recruitment also affects local bone
resorption. Osteocytes, which are buried in the bone matrix,
maintain bone mass principally by serving as a mechano- or
hormonal-sensor in bone. Animal studies suggest that osteocyte
apoptosis occurs in response to OVX
(49) and that apoptotic
osteocytes initiate osteoclast recruitment, eventually leading to
bone resorption.
(11,27,50–52) Consistent with this, we found that in
both control and LID mice there was a twofold increase in
apoptotic osteocyte density 4 weeks after OVX. However, while
in control mice we could detect this increase even 8 weeks after
OVX, LID mice showed no difference in apoptotic osteocyte
density between sham surgery and OVX. Moreover, regardless of
ovarian status, LID mice exhibited a significantly lower apoptotic
osteocyte density, possibly owing to IGF-1-independent anti-
apoptotic actions of increased GH.
(53) Additional work will be
required to define this potential GH-dependent protective
pathway. Invitrostudiescanbeparticularly useful indefiningthe
mechanisms that regulate apoptosis in osteocytes in response to
changes in the levels of endocrine/paracrine regulators.
However, additional in vivo studies also will be necessary to
define the local levels of GH, IGF-1, and the relevant binding
proteins and their changes in response to estrogen depletion.
Nonetheless, our findings suggest that the low osteoclastic
activity in LID mice results from both a reduced osteoclast
recruitment signal (osteocyte apoptosis) and a low number of
osteoclast progenitors (see Fig. 7).
Not only are our findings important to understanding the role
of circulating IGF-1 and GH in mice, but they also appear similar
to clinical observations and may have implications for influen-
cingfracturerisk.Estrogen lossisassociated withendosteal bone
loss that in long bones requires compensation by periosteal new
bone formation to maintain mechanical properties and help to
prevent fracture.
(9,34,54–56) In states of low serum IGF-1 and
estrogen deficiency (i.e., older postmenopausal women),
increases in GH levels could decrease bone loss and enhance
structure, including increases in periosteal bone formation,
overall size, and mechanical integrity.
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